P1.04-026 Coexisting Lung Cancer and Interstitial Lung Disease: A Challenge in Clinical Practice
نویسندگان
چکیده
منابع مشابه
a 2.5 months old girl with interstitial lung disease-a case report
Children interstitial lung (ChILD) disease is a large group of disorders with damage in alveolus and capillary. Although these disorders resemble ILD of adult in nomination, ChILD represents different pathologic and clinical patterns. A 2.5 months old girl, with failure to thrive and grunting and dyspnea, complained of staccato coughs without association with feeding, since she was 15 days o...
متن کاملCLINICAL YEAR IN REVIEW Interstitial lung disease
This article reviews the most important articles published in interstitial lung disease, as reviewed during the Clinical Year in Review session at the 2012 annual European Respiratory Society Congress in Vienna, Austria. Since the recent international guidelines for the management of idiopathic pulmonary fibrosis (IPF), important new evidence is available. The anti-fibrotic drug pirfenidone has...
متن کاملGefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients.
PURPOSE Interstitial lung disease (ILD) is a serious adverse effect of gefitinib. We examined the incidence and clinical characteristics of drug-induced ILD in Korean non-small cell lung carcinoma patients treated with gefitinib. MATERIALS AND METHODS A retrospective cohort study was performed in non-small cell lung cancer (NSCLC) patients who started gefitinib treatment at Seoul National Uni...
متن کاملCystic Lung Disease in a Young man
A 32-year-old man was admitted in the Emergency Department with acute dyspnea secondary to spontaneous pneumothorax. He had history of spontaneous pneumothorax 2 years ago.He was active cigarette smoker (10 pack/year). The family history was unremarkable for lung diseases. Additionally, he had no systemic complaints.The lung HRCT revealed multiple bizarre-shaped cysts distributed in both lungs ...
متن کاملFatal asymmetric interstitial lung disease after erlotinib for lung cancer.
Pulmonary toxicity is a known complication of erlotinib, one of the epidermal growth factor receptor tyrosine kinase inhibitors. It consists of diverse entities such as interstitial pneumonitis, bronchiolitis obliterans with organizing pneumonia and pulmonary fibrosis. In our report, an unusual case of an asymmetric interstitial lung disease was described. A 68-year-old female presented with re...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2017
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2016.11.782